PLos ONE
13, e0197350.
Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.
2018
Synodos for NF2 Consortium, Allaway, Rl, Angus, S.P., Beauchamp, R.L., Blakeley, J.O., Bott, M., Burns, S.S., Carlstedt, A., Chang, L.S., Chen, X., Clapp, D.W., Desouza, P.A., Erdin, S., Fernandez-Valle, C., Guinney, J., Gusella, J.F., Haggarty, S.J., Johnson, G.L., La Rosa, S., Morrison, H., Petrilli, A.M., Plotkin, S.R., Pratap, A., Ramesh, V., Sciaky, N., Stemmer-Rachamimov, A., Stuhlmiller, T.J., Talkowski, M.E., Welling, D.B., Yates, C.W., Zawistowski, J.S., and Zhao, W.N.
Notes: Cell viability results were used to evaluate the effectiveness of agents against schwannoma and meningioma cell systems. (5028)
Expand Full Notes »